BioLizard announces Swiss subsidiary and service offering for AI-powered digital transformation of life sciences at Biopôle in Lausanne
Lausanne (Switzerland) and Ghent (Belgium), 23rd January 2024 - Today we are proud to announce the incorporation of BioLizard SA and the opening of new offices at Biopôle in Lausanne, home to one of the largest biotech hubs in Switzerland. With this new foothold, we continue our international expansion, driving commercial activities, while deepening our service commitment to Swiss partners and clients.
Liesbeth Ceelen, PhD, CEO of BioLizard, said: “With our new subsidiary we will increase our reach and service power within Switzerland, by meeting the need for expertise and tools for digital transformation of biotech companies – including for AI-enabled, user-friendly software and data infrastructure – at Biopôle and across canton borders. Our employees – the ‘Lizards’ – are experts in bioinformatics, AI, data analytics and architecture as well as software development. By working closely with clients to create tailor-made solutions and enable the best data-driven decisions, we leverage the unique knowledge of our team to support the therapeutics, diagnostics, animal health and food & agriculture industries. Biopôle houses 120 companies and provides great conditions for us to engage with the Swiss biotech industry and offer our services exactly where our clients need them, and gain access to highly qualified personnel.”
Switzerland plays a leading role in driving global healthcare innovation, with 20% of European biotech companies headquartered in Switzerland and R&D investments reaching a record level of CHF 2.7 billion in 2022. Biopôle fosters innovation by combining a number of diverse life sciences companies, ranging from small to large, pre-clinical to clinical, and research to service. We know from our clients that IT- and AI-based data solutions have become of paramount importance to drive research forward by accelerating speed, decreasing risk and improving quality of results. With this new subsidiary, we look forward to supporting new and existing partners and thereby contributing to the Swiss biotech landscape.
BioLizard offers support to its Swiss clients in strategic consulting, disease profiling, and drug discovery & development from early stages to clinical trials. We have recently released our BioVerse software platform constituting three applications, for scientific literature searches, microbiome analysis and multi-omics data analysis. The opening of the Swiss office marks the third country BioLizard has expanded to, next to the US and the Netherlands, and our roots in Belgium. To further establish our regional presence, we will be available for meetings at the Sachs European Life Sciences CEO Forum on February 28 and 29 and the Swiss Biotech Days from April 22 to 23, 2024.
BioLizard is a leading multi-national bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry. Headquartered in Ghent, Belgium, BioLizard is the trusted go-to partner for data strategy and execution with companies across the range from drug discovery to clinical research and diagnostics. BioLizard accommodates a uniquely qualified team of 50+ experts, ”The Lizards“, who bring together their expertise and abilities, covering data management, software engineering, bioinformatics, advanced data analytics, and AI. Their joint backgrounds in biology and computer sciences enables them to apply specialist understanding to each client’s data environment, to provide insights and tools that are aligned with the client’s goals and maximize R&D return on investment. For further information, please visit https://lizard.bio/ and follow us on LinkedIn.
The Bio|Verse platform is built to meet the growing needs for bespoke software solutions to maximize the potential of the vast amount of research data generated by biotech and pharma companies. Uniquely, it offers a simple interface for scientists, with or without IT background, enabling effective interaction and data interpretation via data analytics in a tailored environment. BioVerse provides compatibility of all its applications and ensures findable, accessible, interoperable and reusable (FAIR) data management. The platform is designed to ensure operability in any data environment.
BioVerse constitutes three applications:
- Bio|Reflect provides at-a-glance and up-to-date global overviews of publications to support unbiased literature searches
- Pro|Biome applies state-of-the art data analytics to microbiome analysis
- Bio|Mx leverages AI & bioinformatics to efficiently integrate and analyze multi-omics datasets, facilitating next generation target and biomarker discovery.
MC Services AG